← Back to patent-cliff list
非马沙坦钾三水合物/氢氯噻嗪
Tier C — Watch / tradeFimasartan Potassium Trihydrate/Hydrochlorothiazide
韩国保宁制药株式会社
Originator
2013
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：Thiazide-sensitive sodium-chloride cotransporter、AT1
Brand：Kanarb plus、Diarakhor
Indications (approved)：原发性高血压
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Fimasartan Potassium Trihydrate/Hydrochlorothiazide?
Approved indications include: 原发性高血压.
When does the Fimasartan Potassium Trihydrate/Hydrochlorothiazide patent expire?
No public expiry year is available for Fimasartan Potassium Trihydrate/Hydrochlorothiazide yet; this page updates once verified.
How do I get a quote for Fimasartan Potassium Trihydrate/Hydrochlorothiazide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24